Kamala Tamirisa, MD, FACC, Named Next ACC BOG Chair-Elect
The ACC has announced Kamala Tamirisa, MD, FACC, as the next chair-elect of the ACC Board of Governors (BOG). Tamirisa, who serves as the associate professor of internal medicine in the Division of Cardiology and director of electrophysiology research at UT Southwestern Medical Center in Dallas, TX, is currently governor of the ACC Texas Chapter and will assume her new role in April 2027, following ACC.27 in Houston, TX.
New Insights Across CV Medicine Take Center Stage in JACC Journals at AHA 2026
Several studies from AHA 2026 exploring topics like precision screening for elevated lipoprotein(a), emerging cardio-oncology biomarkers, translational models for hypertrophic cardiomyopathy (HCM), and sex differences in heart failure (HF) are among the simultaneous publications included in JACC Journals.
2027 Medicare Physician Fee Schedule Final Rule: An ACC Advocacy Deep Dive
The 2027 Medicare Physician Fee Schedule (PFS) final rule released by the Centers for Medicare and Medicaid Services (CMS) on Nov. 3 includes a number of provisions important to cardiology. ACC Advocacy has developed the following overview addressing some of the most important highlights.
CMS Releases Final 2027 Medicare Physician Fee Schedule and Hospital OPPS Rules
The Centers for Medicare and Medicaid Services (CMS) has released the final 2027 Medicare Physician Fee Schedule (PFS) and the Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System rules. Read on for early quick takes from both rules.
Eagle’s Eye View: Underdiagnosis of AFib in Black Adults; Echocardiographic Evaluation; CAC Scores in Young Adults; Add-On Treatments For Resistant Hypertension
In this week’s View, Dr. Eagle looks at how black adults in disadvantaged neighborhoods are less likely to be diagnosed with atrial fibrillation (AFib).
Eagle’s Eye View: SPECIAL TCT RECAP focusing on four studies: PROGRESS on TAVR & AS; SIMPLAFFY on NOACS & DAPT; SPYRAL AFFIRM on RDN & BP; IRIS MAIN on PCI & CABG
In this special edition of the View, Dr. Eagle looks at four studies presented at the recent TCT Conference that could have immediate effects on your practice.
AI-Enabled Clinician: Reimagining Clinical Research in the Age of AI
In this episode, Dr. Ami Bhatt and Dr. Rashmee Shah delve into how artificial intelligence is transforming the clinical research lifecycle.
IRIS-MAIN: No Statistical Difference in Mortality Between PCI and CABG in Asian Patients With Left Main CAD
No statistically significant difference in long-term all-cause mortality was observed among Asian patients with unprotected left main coronary artery disease (CAD) who underwent PCI or CABG, based on a non-randomized analysis of the IRIS-MAIN registry presented at TCT 2026 and simultaneously published in The Lancet.
Safety and Efficacy of ProtEmbo Device; TAVR vs. SAVR in Patients with Symptomatic Severe AR at 1 Year
The ProtEmbo Cerebral Protection System met its primary safety endpoint but failed to meet its primary efficacy endpoint, adding to uncertainty regarding the routine use of cerebral embolic protection (CEP) in TAVR, according to findings from the PROTEMBO IDE trial presented on the final day of TCT 2026.
EPIC17-VERONICA: Can Platelet Function Testing Guide P2Y12i Deescalation?
In patients deemed to have very low platelet reactivity, switching from more potent P2Y12 inhibitors to clopidogrel did not improve outcomes at one year, according to findings from the EPIC17-VERONICA trial presented at TCT 2026.
